Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(4):259; doi:10.1093/jnci/96.4.259
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Theisen, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Theisen, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

IOM Report Targets Testosterone Therapy

Christine Theisen

The first 10% of the full text of this article appears below.

Studies of testosterone therapy should determine the benefits of treatment before determining risks, and study participants should be limited and carefully screened, a committee of the Institute of Medicine at the National Academies has concluded.

More than 1.75 million prescriptions were written for testosterone in 2002, and a majority of them were written for off-label uses. Federally approved only to treat hypogonadism in men, a condition characterized by little or no natural production of testosterone in the testes, testosterone is popularly touted to help . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?